Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVS Bioventus	$6.97 +5.3%	$6.76	$5.62 ▼ $14.38	$572.54M	0.86	435,925 shs	426,669 shs
CERS Cerus	$1.48 +5.0%	$1.34	$1.12 ▼ $2.54	$269.54M	1.56	1.33 million shs	1.56 million shs
NYXH Nyxoah	$7.55 +0.9%	$7.14	$5.55 ▼ $11.87	$254.77M	1.62	75,692 shs	25,983 shs
OFIX Orthofix Medical	$11.18 +0.3%	$11.78	$10.24 ▼ $20.73	$436.87M	0.8	288,241 shs	419,338 shs
OSUR OraSure Technologies	$3.01 +0.3%	$2.83	$2.36 ▼ $4.92	$224.40M	0.45	753,041 shs	701,586 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVS Bioventus	-2.22%	+1.53%	+1.22%	-29.35%	+15.13%
CERS Cerus	-0.70%	+5.22%	+13.71%	+2.17%	-19.89%
NYXH Nyxoah	+0.13%	-4.47%	-4.71%	+8.88%	+7.32%
OFIX Orthofix Medical	+0.54%	+3.24%	-1.15%	-30.36%	-15.91%
OSUR OraSure Technologies	-0.33%	-0.99%	+1.69%	-9.64%	-29.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BVS Bioventus	3.3784 of 5 stars	3.3	0.0	0.0	2.3	4.2	1.3
CERS Cerus	2.7488 of 5 stars	3.5	4.0	0.0	1.5	1.7	0.6
NYXH Nyxoah	3.2069 of 5 stars	3.5	5.0	0.0	1.6	0.0	0.6
OFIX Orthofix Medical	3.2262 of 5 stars	3.5	2.0	0.0	2.1	3.3	1.3
OSUR OraSure Technologies	2.5165 of 5 stars	1.0	2.0	4.2	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVS Bioventus	2.67	Moderate Buy	$14.33	105.64% Upside
CERS Cerus	3.00	Buy	$3.50	136.49% Upside
NYXH Nyxoah	3.00	Buy	$14.50	92.05% Upside
OFIX Orthofix Medical	3.00	Buy	$21.50	92.31% Upside
OSUR OraSure Technologies	2.00	Hold	$3.00	-0.33% Downside

Current Analyst Ratings Breakdown

Latest OSUR, CERS, BVS, NYXH, and OFIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	OFIX Orthofix Medical	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$16.00
6/6/2025	OFIX Orthofix Medical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/19/2025	OSUR OraSure Technologies	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	In-Line ➝ In-Line	$3.00 ➝ $3.00
5/7/2025	BVS Bioventus	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$15.00
4/21/2025	NYXH Nyxoah	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
4/8/2025	NYXH Nyxoah	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVS Bioventus	$567.70M	1.01	$0.55 per share	12.58	$2.80 per share	2.49
CERS Cerus	$180.27M	1.57	N/A	N/A	$0.31 per share	4.77
NYXH Nyxoah	$4.89M	52.59	N/A	N/A	$3.60 per share	2.10
OFIX Orthofix Medical	$799.49M	0.55	N/A	N/A	$13.07 per share	0.86
OSUR OraSure Technologies	$185.83M	1.21	$0.04 per share	77.27	$5.50 per share	0.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVS Bioventus	-$156.23M	-$0.48	N/A	15.15	N/A	-7.11%	15.61%	4.01%	N/A
CERS Cerus	-$20.92M	-$0.10	N/A	N/A	N/A	-10.23%	-34.81%	-9.68%	7/30/2025 (Estimated)
NYXH Nyxoah	-$64.10M	-$2.13	N/A	N/A	N/A	-1,571.39%	-63.37%	-46.67%	8/5/2025 (Estimated)
OFIX Orthofix Medical	-$126M	-$3.69	N/A	N/A	N/A	-17.78%	-28.15%	-16.51%	8/5/2025 (Estimated)
OSUR OraSure Technologies	-$19.50M	-$0.42	N/A	N/A	N/A	-19.77%	-5.86%	-5.20%	8/5/2025 (Estimated)

Latest OSUR, CERS, BVS, NYXH, and OFIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	NYXH Nyxoah	-$0.49	-$0.63	-$0.14	-$0.63	$1.64 million	$1.12 million
5/1/2025	Q1 2025	CERS Cerus	-$0.05	-$0.04	+$0.01	-$0.04	$47.44 million	$43.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVS Bioventus	N/A	N/A	N/A	N/A	N/A
CERS Cerus	N/A	N/A	N/A	N/A	N/A
NYXH Nyxoah	N/A	N/A	N/A	N/A	N/A
OFIX Orthofix Medical	N/A	N/A	N/A	N/A	N/A
OSUR OraSure Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVS Bioventus	1.85	1.41	0.99
CERS Cerus	1.15	2.32	1.63
NYXH Nyxoah	0.22	3.59	3.35
OFIX Orthofix Medical	0.38	2.71	1.50
OSUR OraSure Technologies	N/A	12.34	10.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BVS Bioventus	62.94%
CERS Cerus	78.37%
NYXH Nyxoah	N/A
OFIX Orthofix Medical	89.76%
OSUR OraSure Technologies	93.50%

Insider Ownership

Company	Insider Ownership
BVS Bioventus	33.00%
CERS Cerus	3.40%
NYXH Nyxoah	N/A
OFIX Orthofix Medical	1.30%
OSUR OraSure Technologies	3.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BVS Bioventus	1,200	82.14 million	54.46 million	Not Optionable
CERS Cerus	290	191.16 million	184.66 million	Optionable
NYXH Nyxoah	110	34.06 million	N/A	Not Optionable
OFIX Orthofix Medical	1,616	39.18 million	38.67 million	Optionable
OSUR OraSure Technologies	840	74.80 million	71.88 million	Optionable

OSUR, CERS, BVS, NYXH, and OFIX Headlines

Recent News About These Companies

Two Sigma Investments LP Takes $552,000 Position in OraSure Technologies, Inc. (NASDAQ:OSUR)

June 9, 2025 | marketbeat.com

Mackenzie Financial Corp Increases Stake in OraSure Technologies, Inc. (NASDAQ:OSUR)

June 4, 2025 | marketbeat.com

OraSure Technologies: Multiple Shots To Deliver Value

May 29, 2025 | seekingalpha.com

OraSure stock rises following Regeneron’s 23andMe acquisition

May 21, 2025 | investing.com

OraSure Technologies (OSUR) Sees Positive Market Reaction | OSUR Stock News

May 19, 2025 | gurufocus.com

OraSure Technologies (OSUR) Maintains In-Line Rating with Evercore ISI Group | OSUR Stock News

May 19, 2025 | gurufocus.com

OraSure Technologies (OSUR) Rises on Regeneron-23andMe Deal

May 19, 2025 | gurufocus.com

OraSure, Targeted Genomics in pact for at-home celiac genetic testing

May 15, 2025 | seekingalpha.com

Targeted Genomics Announces Commercial Collaboration with OraSure Technologies for Direct to ...

May 14, 2025 | gurufocus.com

OraSure Technologies (OSUR) Partners to Enhance At-Home Celiac Testing | OSUR Stock News

May 14, 2025 | gurufocus.com

Targeted Genomics Announces Commercial Collaboration with OraSure Technologies for Direct to Consumer (DTC) Celiac Genetic Testing

May 14, 2025 | tmcnet.com

Earnings call transcript: OraSure’s Q1 2025 beats EPS forecast, stock stable

May 9, 2025 | investing.com

Orasure technologies outlines Q2 2025 revenue guidance of $28.5M-$32.5M amid new product launches and customer expansions

May 9, 2025 | msn.com

OraSure Announces First Quarter 2025 Financial Results

May 8, 2025 | santelog.comS

OraSure reports first quarter loss, but looks forward to emerging as 'stronger enterprise'

May 8, 2025 | wfmz.comW

OraSure Technologies, Inc. (NASDAQ:OSUR) Shares Could Be 35% Above Their Intrinsic Value Estimate

May 8, 2025 | finance.yahoo.com

OraSure Technologies Inc (OSUR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

May 8, 2025 | gurufocus.com

OraSure Technologies Reports Q1 2025 Financial Results

May 7, 2025 | tipranks.com

OraSure Technologies, Inc. (OSUR) Q1 2025 Earnings Call Transcript

May 7, 2025 | seekingalpha.com

OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates

May 7, 2025 | zacks.com

OraSure Technologies Reports Q1 2025 Revenue Decline

May 7, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

D-Wave Is Soaring—But Is ETF Diversification the Better Strategy?
By Nathan Reiff | June 11, 2025
View D-Wave Is Soaring—But Is ETF Diversification the Better Strategy?
3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
By Nathan Reiff | June 9, 2025
View 3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
3 Tech Focused ETFs to Watch as the Market Nears All-Time Highs
By Ryan Hasson | June 11, 2025
View 3 Tech Focused ETFs to Watch as the Market Nears All-Time Highs
Top 3 ETFs Defense Hawks Are Buying
By Nathan Reiff | June 2, 2025
View Top 3 ETFs Defense Hawks Are Buying
Want AI Exposure? These 3 ETFs Offer Different Angles
By Chris Markoch | June 9, 2025
View Want AI Exposure? These 3 ETFs Offer Different Angles

OSUR, CERS, BVS, NYXH, and OFIX Company Descriptions

Bioventus NYSE:BVS

$6.97 +0.35 (+5.29%)

Closing price 04:00 PM Eastern

Extended Trading

$7.30 +0.33 (+4.72%)

As of 04:26 PM Eastern

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Cerus NASDAQ:CERS

$1.48 +0.07 (+4.96%)

Closing price 04:00 PM Eastern

Extended Trading

$1.48 0.00 (0.00%)

As of 06:07 PM Eastern

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Nyxoah NASDAQ:NYXH

$7.55 +0.07 (+0.94%)

Closing price 04:00 PM Eastern

Extended Trading

$7.52 -0.03 (-0.40%)

As of 06:12 PM Eastern

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Orthofix Medical NASDAQ:OFIX

$11.18 +0.03 (+0.27%)

Closing price 04:00 PM Eastern

Extended Trading

$11.18 0.00 (0.00%)

As of 06:14 PM Eastern

Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.

OraSure Technologies NASDAQ:OSUR

$3.01 +0.01 (+0.33%)

Closing price 04:00 PM Eastern

Extended Trading

$3.01 0.00 (0.00%)

As of 04:04 PM Eastern

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time